|
Found 172 result(s) FROM 1963 pages containing the term 'psoriasis'.
Wednesday Oct 21, 2009
Phase 2 Data Support Pfizer's JAK Inhibitor for RA
Two Phase 2 trials reported at ACR show efficacy of JAK inhibitor now in Phase 3...
Tuesday Oct 13, 2009
Protalix Reports First Data on Generic Enbrel™
Plant cell fusion protein would be first “biosimilar” version of etanercept...
Wednesday Sep 30, 2009
FDA Finally OKs Stelara for Psoriasis
The FDA has approved Centocor's Stelara (ustekinumab) for moderate to severe psoriasis...
Thursday Aug 13, 2009
Docs Miss Details in Psoriasis Visits
In-office communication between psoriasis patients and clinicians needs improvement...
Wednesday Aug 05, 2009
Black Box Added to TNF Inhibitors for Kids, Teens
The FDA has expanded TNF blocker “black box” warnings to include lymphoma and other cancers in children and teens, leukemia in all patients, and new-onset psoriasis...
Wednesday Aug 05, 2009
Psoriasis: Not Just Skin Deep
Mark G. Lebwohl, MD says psoriasis affects the heart and other vital organs, and treatment with TNF-blockers may reduce the risk of these comorbidities...
Wednesday Jul 29, 2009
TNF Inhibitors Have Different TB Risks
The risk of developing tuberculosis is 7 to 17 fold higher among patients receiving anti-TNF monoclonal antibody therapy than for those receiving soluble TNF receptors. How can you protect your patients?...
Monday Jun 22, 2009
The Best Biologic for Psoriasis and Psoriatic Arthropathy—Looking at the Trials
A study presented at EULAR 2009 compared the efficacy and safety of different biologics used to treat psoriasis and PsA...
Friday May 22, 2009
Johnson & Johnson Wants Remicade Back
J&J is going to court to end its Remicade partnership with Schering-Plough due to a merger with Merck...
Thursday Apr 09, 2009
Genentech Pulls Psoriasis Drug Raptiva Due to PML
Roche's Genentech unit will pull the psoriasis drug Raptiva® (efalizumab) due to PML risk...
Friday Mar 27, 2009
Fablyn® OK'ed in EU for Osteoporosis, Still on Hold in US
Pfizer-Ligand's Fablyn® (lasofoxifene) has been approved by European regulators, just months after failing to win FDA approval in the US...
Tuesday Mar 17, 2009
New Laser for Psoriasis Aims to Cut Treatment
The excimer laser, best known for its use in eye surgery, is providing some patients with relief from their psoriasis...
Thursday Feb 19, 2009
Raptiva® Pulled in EU After 3rd PML Case; FDA Warns US Docs
European regulators suspended sales of the psoriasis drug Raptiva® after a 3rd PML death, and the FDA warned US doctors of a 4th suspected case...
Wednesday Feb 18, 2009
Ustekinumab Reduces Psoriatic Arthritis Pain, Clears Lesions
Ustekinumab (CNTO 1275), a new monoclonal antibody that blocks interleukin (IL)-12 and IL-23 (IL-23), may help thwart the pain, swelling and lesions of psoriatic arthritis...
Friday Feb 06, 2009
Galderma's Vectical™ Gets FDA OK for Psoriasis
Vectical vitamin D3 ointment has been approved by the FDA for mild-to-moderate plaque psoriasis...
Friday Jan 30, 2009
Psoriasis Gene Studies Fill In More Pieces of the Puzzle
New genetics data suggest novel approaches to psoriasis treatment...
Wednesday Jan 28, 2009
Half of Psoriasis Patients Improve With Online Support Groups
Nearly half of psoriasis patients said their health status and disease severity improved after they joined an online psoriasis support group...
Tuesday Nov 18, 2008
Centocor's Golimumab Gives Durable Skin, Joint Relief in Psoriatic Arthritis, ACR Studies Say
More than half of active psoriatic arthritis patients receiving subcutaneous injections of 50 mg or 100 mg of golimumab (CNTO 148) every 4 weeks showed improvements that lasted through 1 year in the joint and skin symptoms...
Wednesday Oct 15, 2008
Genentech Issues Dear Healthcare Provider Letter Regarding Case of PML in a Psoriasis Patient Under Long-Term Treatment With Raptiva®
The 70-year old patient had received Raptiva® (efalizumab) for >4 years to treat chronic plaque psoriasis before being diagnosed with progressive multifocal leukoencephalopathy...
Wednesday Oct 08, 2008
Incyte's Topical JAK Inhibitor Shows Positive Proof-of-Concept Results in Two Phase IIa Clinical Trials in Patients with Mild-to-Moderate Psoriasis; Phase IIb Expected to Start October 2008
Results from the first study demonstrated that INCB18424 was well tolerated at all doses and significantly improved overall total lesion score (erythema + scaling + thickness)...
Monday Sep 29, 2008
Abbott Reports Continuous Treatment With Humira® Achieves Superior Long-Term Efficacy for Psoriasis Patients in the US and Europe Versus Interrupting Treatment
The findings were from the company's pivotal 52-week REVEAL study and the period of open-label treatment that followed...
Thursday Sep 25, 2008
Centocor’s Ustekinumab Demonstrates Superior Efficacy to Enbrel® (Etanercept) in Treatment of Moderate-to-Severe Plaque Psoriasis
Greater proportion of patients receiving ustekinumab achieved significant skin clearance versus patients receiving Enbrel...
Thursday Sep 18, 2008
GSK, Cellzome Announce Strategic Alliance to Identify Kinase-Targeted Drugs for Inflammatory Diseases
The alliance gives GSK access to Cellzome’s expertise in identifying and developing selective kinase inhibitors and its proprietary Kinobeads™ technology which, by screening compounds in a physiological setting, is designed to improve the predictability of these drug candidates’ performance in clinical testing...
Friday Sep 12, 2008
BioCryst Reports Results From Phase IIa Trial of PNP Inhibitor in Psoriasis; No Evidence of Clinical Efficacy
BCX-4208 is a potent, rationally-designed, inhibitor of PNP—a purine salvage pathway enzyme that is essential for the proliferation of activated T-cells...
Tuesday Aug 26, 2008
After Fits and Starts, New Hope for Psoriasis Patients
Psoriasis patients are finally finding some relief with a new wave of drug treatments known as biologics…
Tuesday Aug 19, 2008
Centocor Says US FDA Extends Review by 3 Months for Ustekinumab’s (CNTO 1275) Biologic License Application to Treat Plaque Psoriasis
Centocor filed an application with the FDA for ustekinumab in late 2007 seeking approval to market the drug to treat adult patients with chronic moderate-to-severe plaque psoriasis...
Wednesday Aug 06, 2008
NeoStrata Reports Novel Nonprescription Coal Tar Solution Provides Significant Benefits Versus Calcipotriol for Moderate Psoriasis
Findings from an ongoing 12-week study demonstrate benefits of a novel, nonprescription topically applied LCD (coal tar) solution (Psorent™) versus calcipotriol cream (Dovonex®) in treatment of moderate plaque psoriasis...
Monday Aug 04, 2008
Manhattan Pharmaceuticals Reports Phase IIa Results of PTH (1-34) for Psoriasis; Cream is Well Tolerated but No Significant Improvement in Treated Lesions Compared With Vehicle
Data from from the phase IIa clinical study of a reformulated topical PTH (1-34) for the treatment of psoriasis did not demonstrate a statistically significant improvement in the overall disease severity of treatment lesions or signs and symptoms of psoriasis compared with vehicle gel...
Wednesday Jul 30, 2008
As Doctors Cater to Looks, Skin Patients Wait
Dermatology is becoming a two-tier business in which cosmetic patients, who are generally seeking more expensive procedures, are given preferential treatment to medical patients…
Monday Jul 28, 2008
Chelsea Therapeutics Granted UK MHRA Approval to Begin Phase II Trial of Droxidopa, a Prodrug of Norepinephrine, in Fibromyalgia
Droxidopa, an orally active synthetic amino acid precursor of norepinephrine (NE), is converted by the body into norepinephrine and as a prodrug of NE, provides replacement therapy for NE deficiency...
Tuesday Jul 22, 2008
Ardea Biosciences Advances RDEA806 Into Phase IIa Proof-of-Concept Study for Gout
Ardea Biosciences has received regulatory approval to begin a phase IIa proof-of-concept clinical trial evaluating RDEA806 in gout patients with hyperuricemia...
Thursday Jul 17, 2008
Classification and Categorization of Psoriatic Arthritis
Researchers in the field of psoriatic arthritis are working to overhaul Moll and Wright’s criteria for the classification and categorization of the disease…
Tuesday Jul 15, 2008
Wyeth Reports European Commission Announces Marketing Authorization for 50 mg Once-Weekly Enbrel® (etanercept) for Patients With Moderate-to-Severe Psoriasis
The European Commission announced a new 50 mg Enbrel® (etanercept) once-weekly dosage regimen as an alternative to the currently approved 25 mg Enbrel twice-weekly regimen for the treatment of moderate-to-severe plaque psoriasis...
Monday Jul 14, 2008
Welichem's Phase I Clinical Trial of Topical WBI-1001 Meets Primary, Secondary Objectives in Psoriasis
Welichem Biotech, a biotechnology company developing therapeutic drugs in the fields of autoimmune, inflammatory diseases, and cancer, announced positive results from a phase I clinical trialevaluating topically applied WBI-1001 in psoriasis patients...
Thursday Jul 10, 2008
Merck Serono Reports EMEA Confirms Positive Benefit-Risk Balance With Raptiva® for the Treatment of Psoriasis; European Commission Approved Product Information Update to Include Data on Up to 3 Years of Treatment
The European Commission has approved an update of the Summary of Product Characteristics (SPC) for Raptiva® (efalizumab) in the treatment of moderate-to-severe chronic plaque psoriasis...
Wednesday Jul 02, 2008
Biotie Reports Positive Phase 1a Data for Anti-VAP-1 Monoclonal Antibody BTT-1023; Dosing Regimens to be Established in RA and Psoriasis Patients
Biotie's first-in-human study of BTT-1023 investigated the safety, tolerability, and pharmacokinetic characteristics of single intravenous doses of the antibody in healthy volunteer subjects...
Tuesday May 20, 2008
Drug Works Well for Moderate-to-Severe Psoriasis
Ustekinumab injections are an efficient long-term treatment for moderate-to-severe psoriasis…
Tuesday May 20, 2008
Warner Chilcott, LEO Pharma Report FDA Approves Taclonex Scalp®, a Once-Daily Therapy for Treatment of Moderate-to-Severe Scalp Psoriasis
The US FDA has approved the new drug application for Taclonex Scalp® topical suspension for the treatment of moderate-to-severe psoriasis vulgaris of the scalp in adults...
Friday May 16, 2008
Centocor Alerts Authorized Distributors and Prescribing Physicians About Stolen Infliximab (Remicade®)
A transport trailer carrying infliximab (Remicade®) was stolen en route to a specialty distributor on May 6, 2008...
Friday May 02, 2008
Genetic Information Nondiscrimination Act Passes Congress, Heads for White House
Both houses of Congress have passed legislation that bans discrimination in employment, insurance, and other areas based on an individual’s genetic makeup, and the bill is expected to be quickly signed into law by President George W. Bush...
Tuesday Apr 22, 2008
New Psoriasis Pill Appears Effective
An oral dose of ISA247, a calcineurin inhibitor, shows promise as a safe and effective treatment for moderate to severe psoriasis…
Monday Apr 21, 2008
Abbott’s Humira® (adalimumab) Approved in Japan for the Treatment of RA
Abbott received approval in Japan for Humira® (adalimumab) to treat RA in patients with inadequate response to conventional therapy...
Friday Apr 04, 2008
Seven New Psoriasis Risk Genes Identified
A genome-wide study has identified 7 new genes that appear to increase a person's risk for psoriasis…
Thursday Mar 27, 2008
Anacor’s Phase IIa Psoriasis Trial of AN2728 Achieves Primary, Secondary Endpoints
Anacor Pharmaceuticals, Inc announced positive results from a phase IIa clinical trial of AN2728, a boron-containing inhibitor of phosphodiesterase-4 (PDE4), in patients with psoriasis...
Thursday Mar 27, 2008
Diabetes Drugs May Prevent Psoriasis
Diabetes drugs such as Avandia® and Actos® may reduce the risk of developing psoriasis…
Thursday Mar 20, 2008
Merrimack Pharmaceuticals Completes Enrollment in a Phase II Study of MM-093, Recombinant AFP, in Patients With RA
Merrimack Pharmaceuticals, Inc's phase II trial to evaluate the safety and efficacy of MM-093, a nonglycosylated, recombinant version of human alpha-fetoprotein (AFP) in patients suffering from rheumatoid arthritis (RA) has completed enrollment...
Tuesday Mar 04, 2008
Karo Bio AB, Zydus Cadila to Develop Selective Glucocorticoid Receptor Modulators to Treat Inflammatory Diseases; Karo Reacquires Rights to SARMs From Radius
Karo Bio AB and Zydus Cadila announced a 3-year research collaboration to discover and develop novel, selective glucocorticoid receptor (GR) modulators for the treatment of inflammatory diseases...
Thursday Feb 21, 2008
Pharmacopeia Advances Chemokine Receptor Antagonist Into Preclinical Development for Inflammatory and Autoimmune Disease Indications
Pharmacopeia Inc announced the advancement of PS031291, a
potent and highly selective oral antagonist at the chemokine receptor
CCR1, as a preclinical development compound from its internal CCR1
discovery program...
Thursday Feb 14, 2008
Celgene Reports More Positive Phase II Data on Apremilast in Psoriasis Patients; to Expand Dosing Level, Duration; Accelerate Advancement in Psoriasis, Psoriatic Arthritis, RA
Celgene Corp announced positive clinical data from a phase II study of apremilast (CC-10004), its lead orally bioavailable, small molecule inhibitor of TNF/PDE4, in patients with moderate-to-severe plaque psoriasis...
Monday Feb 11, 2008
UCB Reports US FDA to Review Cimzia® License Application for Treatment of RA
UCB announced that the US FDA agreed to accept a Biologics License Application for Cimzia®
(certolizumab pegol), a PEGylated and Fc-free anti-TNFα
antibody-fragment therapeutic, for the treatment of adult patients with
active rheumatoid arthritis (RA)...
Friday Feb 08, 2008
Phase III Data Look Good for Ustekinumab (CNTO 1275) in Plaque Psoraisis
Ustekinumab (CNTO 1275), a new monoclonal antibody that blocks interleukin (IL)-12 and IL-23, may hold advantages over existing systemic therapies for chronic plaque psoriasis in terms of its convenience and potentially its safety...
Friday Feb 08, 2008
TNF Inhibitors, Efalizumab, Alefacept Herald New Era in Psoriasis Treatment
New treatment strategies that include TNF-α inhibitors, efalizumab, and alefacept offer better psoriasis control with less toxicity, but still need to be compared with traditional agents in clinical trials...
Wednesday Feb 06, 2008
Trial Data Confirm Dramatic Clearing of Severe Plaque Psoriasis With Infliximab
Data from three randomized, placebo-controlled trials show substantial benefit from Remicade® (infliximab) in moderate-to-severe plaque psoriasis...
Tuesday Feb 05, 2008
Centocor Announces Ustekinumab (CNTO 1275) Biologics License Application Accepted by US FDA for the Treatment of Psoriasis
Centocor, Inc announced that the Biologics
License Application for ustekinumab (CNTO 1275), a fully-human
monoclonal antibody targeting the cytokines interleukin (IL)-12 and
IL-23, has been accepted for review by the US FDA for the treatment of
chronic moderate-to-severe plaque psoriasis in adults...
Monday Feb 04, 2008
Amgen, Wyeth Report Enbrel® (etanercept) Significantly Reduced Levels of CRP, a Marker of Inflammation, in Patients with Moderate-to-Severe Plaque Psoriasis
Amgen Inc and Wyeth Pharmaceuticals
announced findings from a retrospective analysis
demonstrating that Enbrel® (etanercept), a fully human
soluble TNF receptor, reduced C-reactive protein (CRP) in patients with
moderate-to-severe plaque psoriasis...
Tuesday Jan 29, 2008
Association Between Psoriasis and the Metabolic Syndrome
Researchers have found a possible association between psoriasis and the metabolic syndrome, and have suggested possible new treatment options for the management of psoriasis...
Wednesday Jan 23, 2008
Abbott's Humira® Approved in US for Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
Abbott Laboratories announced it has received US FDA approval to market Humira® (adalimumab) for adults with moderate-to-severe chronic plaque psoriasis...
Tuesday Jan 22, 2008
New Jersey Investigating Amgen's Marketing of a Psoriasis Drug
New Jersey's attorney general is investigating biotechnology company Amgen Inc over possible patient confidentiality law violations in their efforts to sell Enbrel®â€¦
Wednesday Jan 16, 2008
Incyte Reports INCB18424, a Selective JAK2 Inhibitor, Shows Initial Positive Clinical Activity With Rapid Onset of Action in RA and Psoriasis
Incyte Corp announced positive clinical proof-of-concept results with its wholly-owned, internally developed, lead JAK2 (Janus-associated kinase 2) inhibitor, INCB18424, in rheumatoid arthritis (RA) and psoriasis...
Wednesday Jan 16, 2008
Etanercept Clears Plaque Psoriasis in Children and Adolescents
Etanercept (Enbrel®) safely reduces disease severity in children and adolescents with moderate-to-severe plaque psoriasis, and improvements are evident as early as the second week of therapy...
Friday Jan 11, 2008
aRigel Initiates Phase I Clinical Trial of JAK3 Inhibitor R348 for RA, Psoriasis, and Other Immune Disorders
Rigel Pharmaceuticals, Inc announced that it has
initiated the enrollment of patients in a phase I clinical study to
evaluate the safety and tolerability of R348, an orally bioavailable,
potent (<100 nM) and selective inhibitor of Janus kinase 3 (JAK3)
as a potential treatment for patients with rheumatoid arthritis,
psoriasis, and other immune disorders...
Tuesday Jan 08, 2008
Tacrolimus in Dermatology—Pharmacokinetics, Mechanism of Action, Drug Interactions, Dosages, and Side Effects
Researchers have assessed the efficacy and safety of tacrolimus treatment in dermatology...
Monday Jan 07, 2008
Abbott's Humira® Approved in the EU for Treatment of Moderate-to-Severe Plaque Psoriasis
Abbott announced it has received marketing authorization from the European Commission for the use of the TNF antagonist Humira® (adalimumab) as a treatment for moderate-to-severe plaque psoriasis. Humira is the first fully human, self-injectable biologic for the treatment of psoriasis...
Tuesday Dec 11, 2007
Identification of Two New Ankylosing Spondylitis Genes Suggest Novel Therapeutic Targets
Genome scans have identified two of the suspected handful of non-MHC genes that appear to collaborate with HLA-B27 in "turning on" disease processes that result in ankylosing spondylitis and other seronegative arthropathies...
Tuesday Nov 20, 2007
Abbott's Humira® Receives Positive Opinion From EMEA for Treatment of Moderate-to-Severe Plaque Psoriasis
Abbott Laboratories announced that the
Committee for Medicinal Products for Human Use (CHMP), granted Abbott a
positive opinion recommending approval of Humira® (adalimumab) for the
treatment of moderate-to-severe plaque psoriasis...
Tuesday Nov 13, 2007
Anti-IL-12/23 Monoclonal Produces Dramatic Results in Psoriatic Arthritis
The anti-IL-12/23 monoclonal antibody ustekinumab produced dramatic, durable improvements in psoriatic arthritis, according to phase II data reported at the American College of Rheumatology...
Friday Nov 09, 2007
Efalizumab Suspected of Triggering Arthritis in Subset of Psoriasis Patients
A small subset of patients treated with efalizumab for severe plaque psoriasis developed new-onset psoriatic arthritis...
Thursday Nov 08, 2007
Centocor, Schering-Plough's Anti-TNF Golimumab Significantly Improved Articular, Skin, and Nail Manifestations in Patients With Psoriatic Arthritis in Phase III Study; Met Primary and Major Secondary Endpoints
Centocor, Inc, a wholly owned subsidiary of Johnson & Johnson, announced that patients with active psoriatic arthritis (PsA) receiving monthly subcutaneous injections of golimumab experienced significant and sustained improvements in the joint and skin manifestations of the disease, according to findings from the largest phase III biologic study (GO-REVEAL trial) in PsA subjects...
Wednesday Nov 07, 2007
Smoking Blamed for 44% of Psoriasis Risk in Current Smokers, 27% of Risk in Past Smokers
Data from the Nurses Health Study II show that smoking plays a major role in causing psoriasis in women, that heavy smoking worsens psoriasis, and that risk reverts to normal only after 20 years of smoking cessation...
Tuesday Nov 06, 2007
Cytokine PharmaSciences Develops Orally Active Form of Semapimod, a Raf Kinase Inhibitor, for Inflammatory and Autoimmune Diseases; Seeks Partner
Cytokine PharmaSciences Inc, a privately-held, global biopharmaceutical company, announced development of an orally active form of semapimod, its anti-inflammatory cytokine compound...
Monday Nov 05, 2007
Manhattan Pharmaceuticals Initiates Phase IIa Study of Topical PTH (1-34) for Psoriasis
Manhattan Pharmaceuticals, Inc, a pharmaceutical company that acquires and develops drug candidates primarily for the treatment of dermatologic and immunologic disorders, announced that the first patient has received the initial dose of topical PTH (1-34) in a US multicenter, randomized, double-blind, vehicle-controlled, parallel group, phase IIa psoriasis study...
Wednesday Oct 31, 2007
Coley Initiates Phase I Study of First-in-Class TLR Antagonist, CPG 52364, for the Treatment of Systemic Lupus Erythematosus
Coley Pharmaceutical Group, Inc, an international biopharmaceutical company having a pipeline of Toll-Like Receptor (TLR) therapeutic product candidates, announced that it has dosed its first subject in a phase I study of its novel, orally-available TLR Therapeutic drug candidate for the treatment of systemic lupus erythematosus (SLE)...
Wednesday Oct 24, 2007
GSK and Tolerx Form Worldwide Collaboration for Development and Commercialization of Otelixizumab (TRX4) for T-Cell Mediated Autoimmune and Inflammatory Diseases
GlaxoSmithKline and Tolerx, Inc announced a worldwide alliance to develop and commercialize otelixizumab (TRX4), a novel humanized anti-CD3 monoclonal antibody that has potential across a broad range of T-cell mediated autoimmune and inflammatory diseases including psoriasis and rheumatoid arthritis...
Friday Oct 19, 2007
Lilly Acquires Exclusive Rights to MacroGenics' Humanized Anti-CD3 Monoclonal Antibody and Will Collaborate to Develop Autoimmune Disease Treatments
Eli Lilly and Co and MacroGenics, Inc have entered into a global strategic alliance to develop and commercialize teplizumab (MGA031 or hOKT3γ1(Ala-Ala)), a humanized, non-Fc receptor binding, anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules, for use in the treatment of multiple T–cell-mediated autoimmune diseases...
Tuesday Oct 09, 2007
Centocor Reports Infrequently-Administered Subcutaneous Injection of Anti-IL-12/23 Antibody, Ustekinumab, Resulted in Long-Term PASI 75 Response in Phase III Study
Centocor, Inc, a wholly owned subsidiary of Johnson & Johnson, announced findings from an international, randomized, double-blind, placebo-controlled phase III study involving 1230 subjects...
Friday Oct 05, 2007
Abbott's Anti-IL-12/23 Antibody, ABT-874, Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
Abbott Laboratories announced positive study data from an extension to a phase II study demonstrating that a majority of moderate-to-severe psoriasis patients who responded to anti-IL-12/23 (ABT-874) after 12 weeks of treatment maintained a high level of response at 24 weeks, following discontinuation of therapy...
Thursday Sep 06, 2007
Knee Monoarthritis May Be a Harbinger of Non-Small-Cell Lung Cancer
Mild-to-moderate knee monoarthritis may be an early warning sign of non-small-cell lung cancer in heavy smokers...
Thursday Aug 16, 2007
Welichem Initiates Phase I Clinical Trial of Topical Cream in Patients With Mild-to-Moderate Psoriasis
Welichem Biotech Inc, a publicly-traded biotechnology company developing therapeutic drugs in the fields of autoimmune diseases and cancer, announced the initiation of a phase I clinical trial of its antipsoriasis candidate WBI-1001, a small synthetic molecule compound originally isolated from bacterial metabolites, and formulated as a topical treatment...
Monday Aug 13, 2007
Can B-Cell Depletion With Rituximab Trigger Psoriasis?
New case studies linking rituximab therapy for RA and SLE with new-onset psoriasis may call for caution on the ever-expanding use of the B-cell depleting drug...Dass S, et al. Arthritis Rheum. 2007;56:2715-2718.
Wednesday Aug 01, 2007
MedImmune Initiates Phase Ib Multidose Trial of Anti-Interferon-α Monoclonal Antibody in Lupus Patients
MedImmune, Inc, a biopharmaceutical company focused on fully human
antibody-based therapeutics, announced it has begun a phase Ib
multidose clinical trial with MEDI-545, a fully human monoclonal
antibody targeting interferon-α, in lupus patients.
Tuesday Jul 31, 2007
Barrier Therapeutics Announces Positive Phase IIb Data With Oral Rambazoleâ„¢ in Moderate-to-Severe Plaque Psoriasis
Barrier Therapeutics, Inc, announced positive results from its phase IIb dose-finding study of oral Rambazoleâ„¢, an investigational all-trans retinoic acid (ATRA) metabolism blocking agent drug candidate, for moderate-to-severe plaque psoriasis.
Monday Jul 23, 2007
BioCryst, Roche Initiate Phase II Study of PNP Inhibitor for Psoriasis
BioCryst Pharmaceuticals, Inc, a leader in the
use of crystallography and structure-based drug design for the
development of novel therapeutics, announced the initiation of the
first phase II study to evaluate BCX-4208/R3421, an orally available,
small molecule, second generation transition-state analog inhibitor of
purine nucleoside phosphorylase (PNP).
Tuesday Jun 26, 2007
Cytos Reports Results From Phase I/IIa Study With Vaccine Candidate CYT007-TNFQb for Treatment of Psoriasis; Demonstrated Safety and Tolerability but Transient Efficacy
Cytos Biotechnology AG, a public biotechnology company that specializes in the discovery, development, and commercialization of a new class of biopharmaceutical products called Immunodrugsâ„¢ reported results from a multicenter, randomized, placebo-controlled, and double-blind combined phase I/IIa study with CYT007-TNFQb, a novel therapeutic vaccine candidate for the treatment of psoriasis and other inflammatory conditions including rheumatoid arthritis (RA)...
Wednesday Jun 13, 2007
Stopping AS May Require Earlier Use of TNF-Inhibitors
Inflammation in AS stops once the subchondral bone is eroded and the bone/cartilage interface disappears, so preventing bone erosion and syndesmophyte formation is likely to require early anti-inflammatory treatment, including TNF-inhibitors...
Monday Jun 11, 2007
Centocor's Remicade® (Infliximab) Receives EU Approval as First and Only Biologic for the Treatment of Pediatric Patients With Severe, Active Crohn's Disease
Centocor, Inc, a wholly owned subsidiary of Johnson & Johnson and Schering-Plough Corp, announced that the European Commission has approved a new indication for Remicade (infliximab) allowing for the treatment of severe, active Crohn's disease (CD) in pediatric patients ages 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator, and primary nutrition therapy, or who are intolerant to, or have contraindications for such therapies...
Friday May 25, 2007
Accumulating Evidence Supports Adalimumab for Severe Psoriatic Arthritis
Adalimumab (Humira®) is safe and effective for patients with active psoriatic arthritis (PsA) who showed an inadequate response to disease-modifying antirheumatic drugs (DMARDs)...
Wednesday May 23, 2007
Celgene to Advance Clinical and Regulatory Development of Oral Anti-Inflammatory Agents Based on Successful Phase II Trial in Psoriasis; Expands Clinical Program to Include RA and PsA
Celgene Corp (SUMMIT, New Jersey), an integrated global biopharmaceutical company engaged in the discovery, development, and commercialization of novel therapies for the treatment of inflammatory diseases and cancer, announced plans to advance its leading oral anti-inflammatory candidates to address a broad range of inflammatory diseases...
Wednesday May 09, 2007
Abbott's ABT-874 Shows Positive Results in Phase II Psoriasis Study
Abbott Laboratories announced positive results from a 12-week, double-blind, placebo-controlled phase II study in which its investigational treatment, ABT-874, a fully human monoclonal antibody designed to target and neutralize interleukin-12 and interleukin-23, significantly reduced psoriasis symptoms in the majority of patients treated...
Wednesday May 02, 2007
Novosom Acquires Exclusive License Option for CD40-Targeted Antisense Inhibitors from Isis; Deal Strengthens Inflammation Therapeutic Development Program
Novosom AG announced that it has purchased an exclusive option from Isis Pharmaceuticals, Inc (CARLSBAD, California) that, if exercised within 6 months, enables the company to acquire an exclusive, worldwide license to antisense inhibitors targeting the CD40 receptor for all indications...
Monday Apr 23, 2007
Rigel Provides Clinical Update of R788 Phase II Trials in ITP and RA
Rigel Pharmaceuticals, Inc, a clinical-stage drug development company, provided an update on R788, currently involved in ongoing phase II clinical trials in immune thrombocytopenic purpura (ITP) and rheumatoid arthritis (RA)...
Monday Apr 16, 2007
Abbott Seeks US and EU Regulatory Approval for HUMIRA® (Adalimumab) in Psoriasis; Receives US FDA Approval in Crohn's Disease
Abbott Laboratories announced that it has simultaneously submitted a supplemental Biologics License Application (sBLA) with the US FDA and a Type II Variation to the European Medicines Agency (EMEA) seeking approval to market HUMIRA® (adalimumab) as a treatment for moderate-to-severe chronic plaque psoriasis, the fifth autoimmune disease targeted for HUMIRA therapy in both the US and Europe...
Wednesday Apr 04, 2007
Repeated B-Cell Depletion Safe, Effective Over 5 Years in RA
B-cell depletion with rituximab was effective for an average of 15 months per cycle and was relatively well tolerated for up to 5 repeat cycles in patients with otherwise refractory RA...
Monday Mar 26, 2007
Astion Pharma Raises $6.5 Million to Advance Dermatology Portfolio Including a Drug Candidate in Preclinical Development for Psoriasis and a Candidate in Phase II Clinical Development for the Treatment of Cutaneous Lupus Erythematosus
Astion Pharma A/S, a clinical-stage pharmaceutical company focusing on the development of treatments for severe skin diseases, announced it has raised approximately $6.5 million of new capital from existing shareholders to fund its development activities in the field of dermatology...
Thursday Mar 15, 2007
Cytochroma Completes Enrollment in Phase II Psoriasis Clinical Trial for CTA018, a Novel Vitamin D Analog
Cytochroma Inc, a privately-held, integrated specialty pharmaceutical company engaged in the development and commercialization of proprietary products related to vitamin D deficiency and novel vitamin D therapies to treat hyperproliferative disorders such as psoriasis and cancer, announced that it has completed the enrollment of patients in a phase II randomized, double-blind, placebo-controlled clinical trial of CTA018, a cream base for chronic plaque psoriasis.
Monday Feb 12, 2007
Biovitrum and Synphora Initiate Phase IIa Study of Prostaglandin Derivative as Psoriasis Treatment
Biovitrum AB, one of the largest biopharmaceutical companies in Europe, and Synphora AB (UPPSALA, Sweden), a privately-owned biotechnology company that focuses on prostanoid chemistry, announced the initiation of a phase IIa clinical trial of Synphora's prostaglandin derivative drug candidate JB991 for the treatment of psoriasis.
Thursday Feb 08, 2007
Centocor Releases Phase II Data on CNTO 1275, a Monoclonal Antibody Targeting IL-12/IL-23, for Chronic Plaque Psoriasis
Centocor, Inc, a wholly owned subsidiary of Johnson & Johnson, announced that phase II data showed that patients with moderate-to-severe plaque psoriasis who received subcutaneous injections of CNTO 1275 experienced significant clearance of skin disease and significant improvements in quality of life...
Tuesday Jan 16, 2007
Can-Fite Completes Enrollment of 250 Patients in Phase IIb RA Trial of CF101, an A3 Adenosine Receptor Agonist; Receives US$1 Million Payment from Seikagaku Corporation
Can-Fite BioPharma Ltd, a clinical-stage drug development company focused on a portfolio of orally bioavailable, highly selective, small molecule A(3) adenosine receptor (A(3)AR) agonists with potent activities in inflammation and cancer, announced the completion of patient enrollment in a phase IIb rheumatoid arthritis (RA) clinical trial of CF101, an A(3)AR agonist...
Wednesday Dec 20, 2006
Celera Identifies Genetic Variations in Genes Encoding IL-12 and IL-23 Predisposing Individuals to Increased Risk for Psoriasis
Celera, an Applera Corporation business, announced findings that variants in the genes encoding interleukin-12 (IL12B) and interleukin-23 (IL23R), involved in regulating the behavior of cells of the immune system, independently contribute to psoriasis risk.
Wednesday Nov 29, 2006
Source MDx Awarded SBIR Phase I Grant; Will Collaborate with Tufts-New England Medical Center to Develop Biomarkers to Predict Responders and Nonresponders to Anti-TNF Therapy for Rheumatoid Arthritis
Source MDx, a molecular diagnostics company, and Tufts-New
England Medical Center (NEMC) announced a
collaboration to investigate the clinical use of RNA-based
molecular diagnostic tests to monitor rheumatoid arthritis (RA) disease
status and response to therapy.
Tuesday Nov 21, 2006
Bioenvision Files to Start Phase I Trials in Germany of Clofarabine Gel for Psoriasis
Bioenvision, Inc, a company focused on the development and marketing of compounds and technologies for the treatment of cancer, announced the filing of a clinical trial authorization (CTA) to begin two phase I studies in Germany of clofarabine gel for the treatment of psoriasis.
Monday Nov 20, 2006
Cytochroma Initiates Phase II Psoriasis Clinical Trial for CTA018, a Novel Vitamin D Analog
Cytochroma Inc, an integrated specialty pharmaceutical company engaged in the development and commercialization of proprietary products related to vitamin D deficiency and novel vitamin D therapies to treat hyperproliferative disorders such as psoriasis and cancer, has initiated the recruitment of patients with chronic plaque psoriasis for a phase II clinical trial with CTA018 cream.
Thursday Nov 16, 2006
Can-Fite Presents Results Showing a Correlation Between High Expression of the Receptor Target for Its Drug CF101 and Rheumatoid Arthritis Patients' Response to the Drug
Can-Fite BioPharma Ltd, a clinical-stage drug development company focused on a portfolio of orally bioavailable, highly selective, small molecule A(3) adenosine receptor (A[3]AR) agonists with potent activities in inflammation and cancer, announced that it presented results showing a correlation between high expression of the receptor target for its investigational A(3)AR agonist CF101 and the response of rheumatoid arthritis (RA) patients to treatment with the drug, at the 70th Annual Meeting of the American College of Rheumatology and the 41st Annual Meeting of the Association of Rheumatology Health Professionals in Washington, DC.
Tuesday Nov 07, 2006
Ablynx, Wyeth Sign Exclusive Research and License Agreement for Nanobodies® Directed at TNF-α and Its Receptors
Ablynx, a biopharmaceutical company engaged in the discovery and development of a novel class of therapeutic proteins based on single-domain antibody fragments (Nanobodies®) announced that they have entered into a research collaboration and exclusive worldwide license agreement with Wyeth Pharmaceuticals (a division of Wyeth) to discover, develop, and commercialize Nanobodies directed at TNF-α and its receptors, targeting diseases in multiple therapeutic areas.
Wednesday Oct 18, 2006
Rigel Selects a Novel JAK3 Inhibitor for Advanced Preclinical Development for Immune-Mediated Diseases
Rigel Pharmaceuticals, Inc., a clinical-stage drug development company focused on small-molecule drugs for the treatment of inflammatory/autoimmune diseases, cancer, and viral diseases, announced that it has selected R348, a potent and selective inhibitor of janus tyrosine kinase 3 (JAK3), to enter preclinical studies to support an investigational new drug application planned for 2007...
Monday Oct 16, 2006
Biovitrum to Cofinance Clinical Development of Synphora's Prostaglandin Derivative (JB991) for Psoriasis
Biovitrum, one of the largest biopharma companies in Europe, announced a development agreement with the Swedish biotechnology company Synphora AB...
Friday Oct 06, 2006
Isotechnika's Calcineurin Inhibitor (ISA247) Receives Regulatory Green Light for Phase III Psoriasis Trials in Canada and Germany, Poland Is Pending
Isotechnika Inc., a biopharmaceutical company focused on the discovery and development of novel immunosuppressive therapeutics for the treatment of autoimmune diseases and for use in the prevention of organ rejection in transplantation, announced that it has received a No Objection Letter from Health Canada and similar approval from the German Competent Authority to conduct a pivotal phase III clinical trial of its lead immunosuppressive, oral calcineurin inhibitor drug candidate, ISA247 (an isomeric cyclosporine A analog mixture), for the treatment of moderate to severe psoriasis...
Thursday Sep 28, 2006
Centocor's Remicade Approved by US FDA for Treatment of Chronic Severe Plaque Psoriasis
Centocor, Inc. (HORSHAM, Pa.), a wholly owned subsidiary of Johnson & Johnson, announced that the US FDA has approved RemicadeR (infliximab) for the treatment of adult patients with chronic severe (ie, extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and for whom other systemic therapies are medically less appropriate.
Tuesday Sep 26, 2006
Can-Fite BioPharma Licenses Its A(3) Adenosine Receptor Agonist (CF101) to Seikagaku to Develop and Market in Japan for Inflammatory diseases
Can-Fite BioPharma Ltd, a clinical-stage drug development company focused on a portfolio of orally bioavailable, highly selective, small-molecule A(3) adenosine receptor (A3AR) agonists with potent activities in inflammation and cancer, announced that it has signed an exclusive license agreement with a Japanese research-based pharmaceutical company, Seikagaku Corporation, to develop and market its lead orally bioavailable A3AR agonist, CF101 (1-deoxy-1-(6-[([3-iodophenyl] methyl) amino]-9H-purin-9-yl)-N-methyl-β-d-ribofuranuronamide), in Japan for the treatment of inflammatory indications including rheumatoid arthritis (RA) but not including ophthalmic indications.
Thursday Sep 14, 2006
Anthera Licenses Portfolio of Anti-Inflammatory Products from Lilly and Shionogi; Raises $36 Million in Venture Financing
Anthera Pharmaceuticals, a privately-held biopharmaceutical company developing drugs for the treatment of inflammatory diseases, announced that it has entered into a license agreement with Eli Lilly and Company and Shionogi & Co., Ltd., under which Anthera has obtained worldwide (except for Japan) development and commercialization rights to an entire platform of clinical and preclinical inhibitors of phospholipase A2 (PLA2) developed by Lilly and Shionogi as part of their collaboration.
Wednesday Sep 13, 2006
Can-Fite BioPharma to Develop Its A3 Adenosine Receptor Agonist (CF101) for Psoriasis
Can-Fite BioPharma, a clinical-stage drug development company focused on a portfolio of orally bioavailable, highly selective, small-molecule A3 adenosine receptor (A3AR) agonists with potent activities in inflammation and cancer, announced the intent to initiate a phase II clinical trial in psoriasis for its lead drug candidate, CF101.
Thursday Aug 31, 2006
Genizon Grants Exclusive License for Crohn's Disease GeneMap to Genentech
Genizon BioSciences, a gene and drug target discovery company, announced a license and collaboration agreement with Genentech, Inc. under which Genizon granted Genentech an exclusive license to Genizon's GeneMap of disease-associated genes generated from a whole genome association study of Crohn's disease patients from the Quebec Founder Population...
Thursday Aug 17, 2006
Early Diagnosis of AS: Dr. Rudwaleit Does the Math to Make It Easy
Diagnosing early ankylosing spondylitis in a patient with chronic back pain may be easier with a simple method based on standard tests and symptoms... Rudwaleit M, et al. Ann Rheum Dis. 2006;65:1251-1252.
Tuesday Aug 15, 2006
Centocor's REMICADE Receives Expanded Psoriatic Arthritis Indication
Centocor, Inc. announced that the US FDA has expanded marketing approval for Remicade® (infliximab) to inhibiting the progression of structural damage and improving physical function in patients with active psoriatic arthritis (PsA), in addition to reducing the signs and symptoms of active arthritis.
Tuesday Aug 01, 2006
Schering-Plough's REMICADE Receives EU Approval as Monotherapy for Treatment of Psoriatic Arthritis; Abbott's HUMIRA Receives FDA Approval for Treatment of Ankylosing Spondylitis
Schering-Plough Corporation announced that the European Commission approved the use of REMICADE® (infliximab) as monotherapy in the treatment of active and progressive psoriatic arthritis (PsA) in patients who show intolerance to methotrexate (MTX) or for whom MTX is contraindicated.
Friday Jul 28, 2006
Serono Initiates First Large-Scale European Pharmaco-Epidemiologic Study to Gather Additional Safety Data on RaptivaR in Psoriasis
Serono announced that it has initiated a prospective 7-year cohort, multi-national, multicenter study in more than 7000 adult patients with moderate-to-severe plaque psoriasis who have been treated with RaptivaR (efalizumab).
Friday Jul 21, 2006
UCB's CIMZIATM Achieves PASI 75 at Week 12 of 83% in Phase II for Psoriasis
UCB announced positive results from the first phase II clinical trial of CIMZIATM (certolizumab pegol, CDP870), the first and only PEGylated Fab' fragment of a humanized anti-TNF-α antibody, in the treatment of patients with moderate-to-severe chronic plaque psoriasis.
Tuesday Jun 20, 2006
VLST Raises $55 Million in Series B Financing to Develop Treatments for Autoimmune and Inflammatory Disorders
VLST Corporation, of Seattle, Washington, announced that it has raised $55 million in Series B financing...
Friday Jun 16, 2006
Will Long-Term Biologic Treatment of Psoriasis Prevent PsA?
A systemic review of biologic therapies for psoriasis supports the early use of these agents for preventing the development of PsA... Boehncke W-H, et al. J Rheumatol [serial online]. 2006;33. Available at: http://www.jrheum.com.
Friday Jun 09, 2006
Cytopia Signs Exclusive License and Collaboration Agreement With Novartis for JAK3 Kinase Inhibitors in Autoimmune Diseases and Transplant Rejection
Cytopia Ltd announced the execution of a worldwide license and R&D collaboration agreement with Novartis to develop orally active, small-molecule therapeutics targeting JAK3 kinase...
Monday Jun 05, 2006
PsA Enthesopathy As Cause of Plantar Fasciitis Responds to TNF Inhibitors
The TNF inhibitors infliximab and etanercept are both effective for the treatment of enthesopathy associated with psoriatic arthritis... Ritchlin CT. J Rheumatol. 15 May 2006; [Epub ahead of print]
Wednesday May 31, 2006
Synta Initiates Phase II Clinical Trials in RA, CVID for Oral Inhibitor of IL-12 and IL-23
Synta Pharmaceuticals Corp announced the dosing of the first patients in its phase IIa clinical studies of apilimod mesylate in RA and CVID...
Wednesday May 17, 2006
Manhattan Pharmaceuticals Delays Phase IIa Trial of Topical PTH (1-34) for Psoriasis
Manhattan Pharmaceuticals, Inc, of New York, NY, announced a delay in the phase IIa dosing study of topical PTH (1-34) for psoriasis...
Thursday May 04, 2006
Adding Alefacept Increases MTX Response in Psoriatic Arthritis
Alefacept plus methotrexate significantly increased response rates in patients with psoriatic arthritis... Mease PJ, et al. Arthritis Rheum. 2006;54:1638-1645.
Monday Apr 17, 2006
LEO Pharma and Warner Chilcott Launch Taclonex®, a Dual-Action, Once-Daily, Topical Therapy for Plaque Psoriasis in the US
Warner Chilcott, of Rockaway, NJ, and LEO Pharma A/S, of Copenhagen, Denmark, announced that Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) is now available for prescription in the US...
Tuesday Apr 11, 2006
Biogen Idec to Sell Worldwide Rights to Its Psoriasis Drug Amevive to Astellas for $60 Million
Astellas Pharma US, Inc, of Deerfield, Illinois, and Biogen Idec Inc, of Cambridge, Massachusetts, announced an agreement for Astellas to purchase the worldwide rights, in all indications, to Amevive® (alefacept)...
Tuesday Apr 11, 2006
Leflunomide is an Effective Treatment for Psoriatic Arthritis (PsA) and Plaque Psoriasis
Once-daily oral leflunomide is a safe and effective treatment for psoriatic arthritis (PsA) and plaque psoriasis... Nash P, et al. Dermatology. 2006;212:238-249.
Tuesday Apr 04, 2006
New Research Suggests That the Psoriasis Susceptibility I (PSORS1) Gene Has Been Identified
Previous studies have narrowed the interval containing PSORS1 to a 300-kilobase (kb)region in the major histocompatibility locus (MHC), which includes HLA-C and at least 10 other genes. New evidence suggests that HLA-Cw6 is the PSORS1 allele that confers susceptibility to early-onset psoriasis... Nair RP, et al. Am J Hum Genetics. 2006;78:827-851.
Tuesday Apr 04, 2006
Merrimack Pharmaceuticals, Inc, Raises $65 Million to Support Continued Clinical Development of Human Alpha-fetoprotein in RA and Psoriasis
Merrimack Pharmaceuticals, Inc, of Cambridge, Massachusetts, announced that it has raised $65 million in a Series E private equity financing to advance the company's lead product, MM-093, a recombinant version of human alpha-fetoprotein (hAFP)...
Tuesday Mar 14, 2006
York Pharma Announces Positive Phase II Data for Topical Carbenoxolone in Psoriasis
York Pharma plc, of Hitchin, UK, announced that its lead vitamin A pathway inhibitor, carbenoxolone...
Monday Mar 06, 2006
Phase III Data for Centocor's Remicade® Show Rapid and Marked Improvement in Moderate to Severe Plaque Psoriasis
Centocor, Inc, of Horsham, Pennsylvania, announced the results from its phase III EXPRESS II study of Remicade® (infliximab)...
Wednesday Mar 01, 2006
CombinatoRx Drops Its Phase IIa Oral Product Candidate (CRx-140) for Psoriasis; Drug Candidate CRx-102 Demonstrates Positive Phase II Study Results in Hand Osteoarthritis
CombinatoRx Inc, of Boston, Massachusetts, announced the discontinuance of its phase IIa drug candidate, CRx-140...
Thursday Feb 23, 2006
G2 Inflammation Pty Ltd Signs Deal With Novo Nordisk for Anti-C5a Receptor Antibody for the Treatment of RA and Other Inflammation-Mediated Diseases
G2 Inflammation Pty Ltd (G2I) announced a research, development, and licensing agreement with the Danish healthcare company Novo Nordisk to advance G2's Neutrazumab...
Friday Feb 17, 2006
Chelsea Therapeutics Raises $21.5 Million in a Private Placement to Advance Its Antifolate Compound into Phase II trials for RA and Psoriasis
Chelsea Therapeutics International, Ltd, of Charlotte, NC, announced that it has completed a private placement of its common stock...
Monday Feb 13, 2006
QuatRx Files for $86.25 Million IPO, Seeks Partner for Phase IIb Trial of Vitamin D Analogue for Psoriasis
QuatRx Pharmaceuticals Co of Ann Arbor, Michigan, announced that it has filed a registration statement with the US Securities and Exchange Commission...
Monday Feb 13, 2006
AnGes MG and Seikagaku End Joint Development Program for NFkB Decoy-Oligo-Based Intraarticular Injection for RA and OA
AnGes MG, Inc, headquartered in Osaka, Japan, and Seikagaku Corporation of Tokyo, Japan, announced that they have agreed to end their joint development program of NF-kappa B...
Friday Feb 03, 2006
Seal Oil May Lead to Subjective Improvements in Psoriatic Arthritis
Seal oil, rich in omega-3s, may improve psoriatic arthritis patients' global assessment of their disease, suggesting a trend toward a decrease in the number of tender joints, possibly due to seal oil's anti-inflammatory effects... Madland TM, et al. J Rheum. 2006;33:307-10.
Wednesday Jan 25, 2006
Theramed Licenses Sigmasporin® (Cyclosporine) From EMS Sigma Pharma; Will Seek Approval to Market for RA and Psoriasis
Theramed Corporation, of Mississauga, Ontario, Canada, announced that it has entered into a licensing and distribution agreement with Nature's Plus...
Monday Jan 23, 2006
BMS Initiates Phase I Trials for Pharmacopeia's p38 Kinase Inhibitor Targeting RA
Pharmacopeia, of Princeton, NJ, announced that its marketing partner Bristol-Myers Squibb will commence phase I clinical trials...
Wednesday Jan 18, 2006
Combination of cDNA Expression Library and Whatman Protein Microarray Technology Led to Identification of Potential Autoantigens in the Pathogenesis of Alopecia Areata
Whatman, plc (Middlesex, UK), and Protagen, AG (Dortmund, Germany), have issued a joint statement announcing that the combination of two promising technologies...
Wednesday Jan 11, 2006
Manhattan's PTH 1-34, a Topical Treatment for Psoriasis, Enters Phase IIa Trials
Manhattan Pharmaceuticals, Inc, of New York City, announced the initiation of a phase IIa clinical study of PTH 1-34, a parathyroid hormone-related peptide analog, for the topical treatment...
Wednesday Jan 04, 2006
Synta to Advance Clinical Development of IL-12/IL-23 Inhibitor for Crohn's Disease and RA
Synta Pharmaceuticals of Lexington, Massachusetts, announced that it will focus its clinical development efforts in 2006 on STA-5326, an oral interleukin (IL)-12/IL-23 inhibitor...
Thursday Dec 22, 2005
Studies Evaluate Relationship Between Smoking, Obesity, and Exacerbation of Psoriasis
New research into the behavioral and environmental determinants of psoriasis has linked obesity and smoking with exacerbation of the disease, calling attention to the importance of weight reduction and smoking cessation in such patients…Fortes C, et al. Arch Dermatol. 2005;141:1580-1584.
Thursday Dec 22, 2005
TolerRX Initiates Phase Ib Trials of Novel Antibody Therapies for Psoriasis and Cutaneous Lupus Erythematosus
TolerRX, Inc, of Cambridge, Massachusetts, announced the initiation of a phase Ib study of the monoclonal antibody TRX4 in patients with moderate-to-severe...
Sunday Dec 18, 2005
Etanercept May Be Effective for the Depression and Fatigue of Psoriasis
A new phase III trial has found that the tumor necrosis factor-alpha (TNF-α) inhibitor etanercept not only improves the clinical manifestations of psoriasis but also relieves the fatigue and depression associated with the disease. The findings point to the role higher concentrations of proinflammatory cytokines such as TNF-α have in major depressive symptoms…. Tyring S, et al. Lancet [serial online]. December 15, 2005.
Monday Dec 05, 2005
Roche and BioCryst Collaborate on Phase I Compound for Autoimmune Diseases and Transplant Rejection
Roche Pharmaceuticals of Nutley, New Jersey, and BioCryst Pharmaceuticals, Inc, of Birmingham, Alabama, have announced...
Tuesday Nov 29, 2005
Galderma Laboratories Receives FDA Approval for Clobex® Spray for Psoriasis
Galderma Laboratories of Fort Worth, Texas, announced that the US Food and Drug Administration has granted marketing approval for Clobex® ...
Monday Oct 17, 2005
Infliximab Found Highly Effective for Skin and Nail Psoriasis
Infliximab (Remicade®) monotherapy shows rapid onset of action and sustained efficacy as both induction and maintenance therapy for patients with moderate-to-severe skin and nail psoriasis, according to the results of a new multicenter Phase III study ... Reich K, et al. Lancet 2005;366:1367-1374.
Wednesday Oct 12, 2005
Centocor Obtains Approval in Europe for Remicade® for Psoriasis
Centocor, Inc, and its marketing partner, Schering-Plough Corporation, have announced that the European Commission has granted approval of RemicadeR (infliximab)...
Wednesday Sep 28, 2005
New-Onset or Exacerbation of Psoriatic Skin Lesions in RA Patients on Tumor Necrosis Factor-Alpha Antagonists
Nine rheumatic arthritis (RA) patients treated with 3 different tumor necrosis factor-alpha (TNF-α) antagonist formulations developed new-onset or an exacerbation of psoriatic lesions, despite the efficacy of TNF-α antagonists in treating such psoriatic lesions in the past. These first-ever reported cases will likely spur further analysis of the unexpected phenomenon...Kary S, et al. Ann Rheum Dis. Online First. September 8, 2005.
Tuesday Aug 02, 2005
Etanercept Does Not Increase Risk of Squamous Cell Carcinoma in RA Patients
Unlike cyclosporine, etanercept does not appear to increase risk of skin cancer in rheumatoid arthritis (RA) patients... Lebwohl M, et al. Arch Dermatol. 2005;141:861-864.
Tuesday Jul 12, 2005
Amgen, Massachusetts General Hospital in Enbrel Royalty Dispute
The Boston Globe reported that litigation might be filed to resolve a dispute between Amgen Inc and Massachusetts General Hospital in Boston regarding royalty payments received by the hospital that Amgen, the manufacture of Enbrel, contends are in excess of the terms of the licensing agreement.
Wednesday Jun 22, 2005
Phytomedics In-Licenses Anti-Inflammatory Sesquiterpene Lactones
Phytomedics Inc, a Dayton, New Jersey-based developer of novel botanical therapeutics, announced that it has acquired exclusive US licensing rights from Louisiana State University in Baton Rouge for an invention pertaining to sesquiterpene (terpene compounds with 15 carbon atoms) lactones (a cyclic ester) and sesquiterpene lactone-containing plant extracts for the treatment of severe inflammatory disorders such as psoriasis, pemphigus vulgaris, sepsis, and postreperfusion injury.
Thursday Jun 16, 2005
Chelsea Launches Phase I Trial of Its Lead Antifolate Compound
Chelsea Therapeutics, Inc. announced the initiation of a Phase I clinical trial in the UK of its lead orally available, metabolically inert antifolate (CH-1504), which, in a nonpivotal, independent, 6-month pilot clinical study involving 20 rheumatoid arthritis (RA) patients in Peru suggested a lower toxicity and improved tolerability, and increased effectiveness versus methotrexate (MTX), even among patients who had previously failed to demonstrate improvement with MTX.
Wednesday Jun 15, 2005
Alefacept in Combination With Methotrexate Evaluated for the Treatment of Psoriatic Arthritis
A 6-month study of the memory T cell suppressor alefacept suggests that the agent will be an effective tool in the armamentarium against PsA... Presented at: Annual European Congress of Rheumatology of EULAR; June 8-11, 2005; Vienna, Austria.
Wednesday Jun 15, 2005
Etanercept Expands PsA Indication to Include Improvement of Physical Function
Amgen Inc and Wyeth Pharmaceuticals announced that the US Food and Drug Administration (FDA) expanded the marketing approval of Enbrel® (etanercept) to include the improvement of physical function in patients with psoriatic arthritis (PsA).
Thursday Jun 09, 2005
AVANIR/Novartis Agreement: Develop MIF Therapies for Inflammatory Diseases
AVANIR Pharmaceuticals, a drug discovery and development company, announced the signing of an agreement with Novartis Pharmaceutical Corp to develop orally active small molecule therapeutics targeting macrophage migration inhibitory factor (MIF), a proinflammatory cytokine that is thought to play a critical role in the pathology of inflammatory diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
Friday Jun 03, 2005
Recombinant Version of Alpha-Fetoprotein May Hold Promise in RA and Other Autoimmune Diseases
As a Phase II trial begins, experts are cautiously optimistic that the experimental immunomodulating agent may be safer than existing RA treatments, and that the work may help explain why RA tends to remit during pregnancy...National Jewish Medical and Research Center [press release]; June 2, 2005.
Tuesday May 17, 2005
Infliximab Approved for Treatment of Psoriatic Arthritis
Infliximab joins etanercept as an anti-TNF-α treatment option for patients with active psoriatic arthritis...FDA approves Remicade® for ninth indication: psoriatic arthritis [press release]. Malvern, Pa: Centocor, Inc; May 17, 2005.
Wednesday Apr 06, 2005
Study Links TNF Inhibitors to Dermatologic Problems in Rheumatoid Arthritis Patients
Although a causative relationship has yet to be established, the new data put physicians on alert for a "less than major complication" Flendrie M, et al. Arthritis Res Ther. 2005;7:666-676.
Tuesday Mar 08, 2005
Phase II Study of Recombinant Human Alpha-Fetoprotein Initiated in Patients with Rheumatoid Arthritis
Alpha-fetoprotein, which is produced by the fetus during pregnancy, is associated with remission of autoimmune diseases during the third trimester, when it reaches peak levels in maternal serum.
Monday Mar 07, 2005
Latest Trial Results for Biologics in Psoriatic Arthritis
Highlighted results from the American Academy of Dermatology meeting confirm the efficacy of anti-TNF therapy in treating psoriatic arthritis...63rd Annual Meeting of the American Academy of Dermatology, February18-22, 2005; New Orleans, La.
Sunday Mar 06, 2005
Oral Formulation of a Small Molecule Kinase Inhibitor in Phase I Study for Rheumatoid Arthritis
A Phase I clinical trial has been initiated to study the safety and pharmacokinetics of a novel candidate drug for rheumatoid arthritis (RA), R406, an orally administered small molecule syk kinase inhibitor that blocks both IgG and IgE activation of mast cells, macrophages, and B cells.
Friday Feb 18, 2005
Public Outcry Over Embattled Pain Relievers at FDA Advisory Panel Hearing
Some called for the withdrawal of all coxibs, while others pleaded for a return of the withdrawn rofecoxib (Vioxx) during public testimony at the FDA advisory meeting... US FDA Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee; February 17, 2005.
Thursday Feb 17, 2005
Anti-CCP Antibodies Detected in Psoriatic Arthritis Patients
New research suggests that the specificity of this marker may lead to more precise diagnostic criteria for this broad spectrum disease...Vander Cruyssen B, et al. Ann Rheum Dis. 2005. [Epub ahead of print]
Thursday Feb 03, 2005
Crohn's Disease Patients With Attenuated Response to Infliximab May Respond to Adalimumab
Mimicking the paradigm seen with TNF-blockade in rheumatoid arthritis, preliminary data suggest that switching infliximab nonresponders to adalimumab may improve the clinical response and reduce disease activity...Papadakis KA. Am J Gastroenterol. 2005;100:75-79.
Wednesday Oct 27, 2004
Anti-TNF Drugs Appear to Show Benefits in Most Ankylosing Spondylitis Patients and May Also Improve Psoriatic Arthritis
Recent study findings indicate that ankylosing spondylitis and psoriatic arthritis may respond well to infliximab, etanercept, and adalimumab... Rudwaleit M, Sieper J… Z Rheumatol. 2004;63:193-202.
Wednesday Oct 27, 2004
Anti-TNF Drugs Appear to Show Benefits in Most Ankylosing Spondylitis Patients – and May Also Improve Psoriatic Arthritis
Recent study findings indicate that ankylosing spondylitis and psoriatic arthritis may respond well to infliximab, etanercept, and adalimumab... Rudwaleit M, Sieper J… Z Rheumatol. 2004;63:193-202.
Friday Oct 22, 2004
Infliximab Therapy Markedly Improves Skin Symptoms in Psoriatic Arthritis
Independent of the arthritis response, clinicians should continue to use the anti-tumor necrosis factor agent infliximab for patients with active psoriatic arthritis because the drug markedly reduces skin symptoms... Mease P, et al. Presented at: Annual Meeting of the American College of Rheumatology; October 20, 2004; San Antonio, Tex.
Wednesday Oct 20, 2004
Adalimumab Markedly Reduces Psoriatic Arthritis Symptoms
Striking benefits are shown for psoriatic arthritis patients' skin and joint symptoms with adalimumab vs placebo... Mease PJ, et al. Presented at Annual Meeting of the American College of Rheumatology; October 19, 2004; San Antonio, Texas
Wednesday Aug 18, 2004
Study Shows that Etanercept (EnbrelR) Reduces Joint Symptoms, Improves Psoriatic Lesions, and Inhibits Radiographic Progression in Patients with Psoriatic Arthritis
In a study described in the July issue of Arthritis and Rheumatism, Mease and colleagues found that etanercept significantly improved the clinical symptoms and skin lesions of psoriasis in patients with psoriatic arthritis. (Mease PJ, et al. Arthritis Rheum. 2004;50:2264-2272.)
Wednesday Jul 28, 2004
Survey Raises Awareness About the Impact of Psoriasis on Relationships and Daily Life
The results of a national survey emphasize the impact of psoriasis on intimate relationships, social activities, and other aspects of daily life.
Wednesday Jul 14, 2004
Mycobacterial Vaccine Less Effective than Immunotherapies in Treatment of PSA
|
